G-Quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3′ telomeric overhang in cancer cells

Oncogene

Volumn 25, Issue 13, 2006, Pages 1955-1966

  Tahara, H ^a   Shin ya, K ^b   Seimiya, H ^c   Yamada, H ^a   Tsuruo, T ^c   Ide, T ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

3 telomeric overhang; G quadruplex; Telomere; Telomestatin; TRF2

Indexed keywords

TELOMERASE INHIBITOR; TELOMERIC REPEAT BINDING FACTOR 2; TELOMESTATIN;

ANAPHASE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL DEATH; CHROMOSOME STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG SELECTIVITY; ENZYME ACTIVITY; EPITHELIUM CELL; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TELOMERE;

ANAPHASE; BREAST NEOPLASMS; CELL DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; FEMALE; FIBROBLASTS; HELA CELLS; HUMANS; NUCLEAR PROTEINS; OXAZOLES; TATA BOX BINDING PROTEIN-LIKE PROTEINS; TELOMERE; TUMOR CELLS, CULTURED;

EID: 33645280314     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209217     Document Type: Article

References (45)

1. Akiyama M, Hideshima T, Shammas MA, Hayashi T, Hamasaki M, Tai YT et al. (2003). Cancer Res 63: 6187-6194.
2. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB et al. (1998). Science 279: 349-352.
3. Broccoli D, Smogorzewska A, Chong L, de Lange T. (1997). Nat Genet 17: 231-235.
4. Carney SA, Tahara H, Swartz CD, Risinger JI, He H, Moore AB et al. (2002). Lab Invest 82: 719-728.
5. Fang G, Cech TR. (1993a). Biochemistry 32: 11646-11657.
6. Fang G, Cech TR. (1993b). Cell 74: 875-885.
7. Giraldo R, Suzuki M, Chapman L, Rhodes D. (1994). Proc Natl Acad Sci USA 91: 7658-7662.
8. Gomez D, Paterski R, Lemarteleur T, Shin-Ya K, Mergny JL, Riou JF. (2004). J Biol Chem 279: 41487-41494.
9. Gowan SM, Harrison JR, Patterson L, Valenti M, Read MA, Neidle S et al. (2002). Mol Pharmacol 61: 1154-1162.
10. Gowan SM, Heald R, Stevens MF, Kelland LR. (2001). Mol Pharmacol 60: 981-988.
11. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H et al. (1999). Cell 97: 503-514.
12. Gu J, Spitz MR, Zhao H, Lin J, Grossman HB, Dinney CP et al. (2005). Carcinogenesis 26: 1741-1747.
13. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A et al. (1999). Nat Med 5: 1164-1170.
14. Han H, Hurley LH. (2000). Trends Pharmacol Sci 21: 136-142.
15. Hanaoka S, Nagadoi A, Nishimura Y. (2005). Protein Sci 14: 119-130.
16. Hirose M, Abe-Hashimoto J, Ogura K, Tahara H, Ide T, Yoshimura T. (1997). J Cancer Res Clin Oncol 123: 337-344.
17. Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T. (1999). Science 283: 1321-1325.
18. Kim MY, Gleason-Guzman M, Izbicka E, Nishioka D, Hurley LH. (2003). Cancer Res 63: 3247-3256.
19. Kim MY, Vankayalapati H, Shin-Ya K, Wierzba K, Hurley LH. (2002). J Am Chem Soc 124: 2098-2099.
20. Kondo S, Tanaka Y, Kondo Y, Hitomi M, Barnett GH, Ishizaka Y et al. (1998). Faseb J 12: 801-811.
21. Makarov VL, Hirose Y, Langmore JP. (1997). Cell 88: 657-666.
22. Mergny JL, Helene C. (1998). Nat Med 4: 1366-1367.
23. Nakamura Y, Hirose M, Matsuo H, Tsuyama N, Kamisango K, Ide T. (1999). Clin Chem 45: 1718-1724.
24. Nakanishi K, Kawai T, Kumaki F, Hiroi S, Mukai M, Ikeda E et al. (2003). Clin Cancer Res 9: 1105-1111.
25. Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H et al. (1998). Nat Genet 18: 65-68.
26. Nijjar T, Bassett E, Garbe J, Takenaka Y, Stampfer MR, Gilley D et al. (2005). Oncogene 24: 3369-3376.
27. Parkinson GN, Lee MP, Neidle S. (2002). Nature 417: 876-880.
28. Riou JF, Guittat L, Mailliet P, Laoui A, Renou E, Petitgenet O et al. (2002). Proc Natl Acad Sci USA 99: 2672-2677.
29. Rosu F, Gabelica V, Shin-ya K, De Pauw E. (2003). Chem Commun (Camb): 2702-2703.
30. Seimiya H, Muramatsu Y, Ohishi T, Tsuruo T. (2005). Cancer Cell 7: 25-37.
31. Seimiya H, Muramatsu Y, Smith S, Tsuruo T. (2004). Mol Cell Biol 24: 1944-1955.
32. Seimiya H, Oh-hara T, Suzuki T, Naasani I, Shimazaki T, Tsuchiya K et al. (2002). Mol Cancer Ther 1: 657-665.
33. Shay JW, Wright WE. (2005). Cancer Cell 7: 1-2.
34. Shin-ya K, Wierzba K, Matsuo K, Ohtani T, Yamada Y, Furihata K et al. (2001). J Am Chem Soc 123: 1262-1263.
35. Smogorzewska A, van Steensel B, Bianchi A, Oelmann S, Schaefer MR, Schnapp G et al. (2000). Mol Cell Biol 20: 1659-1668.
36. Stansel RM, de Lange T, Griffith JD. (2001). Embo J 20: 5532-5540.
37. Tahara H, Kusunoki M, Yamada Y, Matsumura S, Ide T. (2005). Nat Meth 2: 829-831.
38. Tahara H, Nakanishi T, Kitamoto M, Nakashio R, Shay JW, Tahara E et al. (1995). Cancer Res 55: 2734-2736.
39. Takai H, Smogorzewska A, de Lange T. (2003). Curr Biol 13: 1549-1556.
40. Tauchi T, Shin-Ya K, Sashida G, Sumi M, Nakajima A, Shimamoto T et al. (2003). Oncogene 22: 5338-5347.
41. van Steensel B, Smogorzewska A, de Lange T. (1998). Cell 92: 401-413.
42. Williamson JR, Raghuraman MK, Cech TR. (1989). Cell 59: 871-880.
43. Wright WE, Tesmer VM, Huffman KE, Levene SD, Shay JW. (1997). Genes Dev 11: 2801-2809.
44. Zahler AM, Williamson JR, Cech TR, Prescott DM. (1991). Nature 350: 718-720.
45. Zhang X, Mar V, Zhou W, Harrington L, Robinson MO. (1999). Genes Dev 13: 2388-2399.